Riskpilot← Back to searchSign inGet full accessBasimed AB
ABActiveOrg 5568366693StockholmMedical specialists activities · NACE 8622Est. 20111 employees
Revenue 2025
SEK 1,5M
-10% vs 2024
EBITDA margin
30.5%
-22% vs 2024
Equity ratio
37.0%
Financial strength
Net profit 2025
SEK 273K
-32% vs 2024
| Revenue | SEK 1,5M | -10% |
| EBITDA | SEK 471K | -22% |
| Net profit | SEK 273K | -32% |
| Total assets | SEK 1,8M | +34% |
| Equity | SEK 657K | +36% |
| Employees | 1 | — |
Legal name
Basimed AB
Org number
5568366693
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
3 januari 2011
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Föremålet för bolagets verksamhet är att tillhandahålla medicinska tjänster och därmed förenlig verksamhet.
Address
Stockholm
Email
johanna.sundborg@luki.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 665 | 1 564 | 1 920 | 1 720 | 1 541 |
| Staff expenses | — | −976 | −477 | −142 | −107 |
| EBITDA | −174 | −437 | 611 | 606 | 471 |
| Depreciation & amort. | −10 | −10 | −10 | −10 | −10 |
| EBIT | −184 | −447 | 601 | 596 | 460 |
| Net financials | 30 | 1 | −1 | 12 | 26 |
| Profit before tax | 19 | −123 | 445 | 526 | 357 |
| Tax | −11 | — | −97 | −124 | −84 |
| Net profit | 8 | −123 | 348 | 402 | 273 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1 819 | 767 | 1 400 | 1 323 | 1 776 |
| Equity | 922 | 174 | 452 | 484 | 657 |
| Long-term debt | 0 | — | 200 | 0 | — |
| Short-term debt | 375 | 393 | 394 | 404 | 554 |
| Total debt | 375 | 393 | 594 | 404 | 554 |
EBITDA margin
30.5%
This company
15.8%
Market median
+93% vs market
20212025
Equity ratio
37.0%
This company
38.2%
Market median
+3% vs market
20212025
Return on equity
41.5%
This company
18.4%
Market median
+126% vs market
20212025
Net profit margin
17.7%
This company
8.1%
Market median
+119% vs market
20212025
Asset turnover
0.87×
This company
1.12×
Market median
+22% vs market
20212025
Debt / equity
1.70×
This company
0.62×
Market median
-174% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-07-01 – 2021-06-30
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
AE Chief Executive Officer | Chief Executive Officer | 2022 |
LM Audit | Audit | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Basimed AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ann Elisabeth Moor | Chief Executive Officer | 0 companies |
| Linus Mikael Nilsson | Audit | 0 companies |
| John Hol Michael Larsson | Deputy Board Member | 0 companies |